Evidence map›Paper›PMID 34759915›Full record

ArticleFrontiers in immunology2021

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2.

Bruce D Wines, Halina M Trist, Sandra Esparon, Rachael E Impey, Graham A Mackay, Robert K Andrews, Tatiana P Soares da Costa, Geoffrey A Pietersz, Ross I Baker, P Mark Hogarth

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Bruce D WinesImmune Therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
Halina M TristImmune Therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
Sandra EsparonImmune Therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
Rachael E ImpeyDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Graham A MackayDepartment of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, Australia.
Robert K AndrewsDepartment Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Tatiana P Soares da CostaDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Geoffrey A PieterszImmune Therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
Ross I BakerPerth Blood Institute, Murdoch University, Perth, WA, Australia.
P Mark HogarthImmune Therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
Burnet Institute · AULa Trobe University · AUUniversity of Melbourne · AUAustralian National University · AUBaker Heart and Diabetes Institute · AUMurdoch University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FcγR activity underpins the role of antibodies in both protective immunity and auto-immunity and importantly, the therapeutic activity of many monoclonal antibody therapies. Some monoclonal anti-FcγR antibodies activate their receptors, but the properties required for cell activation are not well defined. Here we examined activation of the most widely expressed human FcγR; FcγRIIa, by two non-blocking, mAbs, 8.26 and 8.2. Crosslinking of FcγRIIa by the mAb F(ab')

Indexed as

Antibodies, MonoclonalAntibody-Dependent Cell CytotoxicityBinding SitesEpitopesHumansImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsMutationPhosphorylationPlatelet ActivationProtein BindingReceptors, FcReceptors, IgGAntibodies, MonoclonalEpitopesFc gamma receptor IIAImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsReceptors, FcReceptors, IgGantibody dependent cellular cytotoxicity (ADCC)effector functionFc receptorFcγRIIaIgGmAb - monoclonal antibody

Identifiers

PMID34759915
PMCPMC8573391
OpenAlexW3207993638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.